MIST

Over the past six months, Milestone Pharmaceuticals' stock price has been impacted by several key events. CARDAMYST received FDA approval in December 2025, which was a positive catalyst, although shares fell the day after the news. In March 2025, the company received a Complete Response Letter (CRL) from the FDA, causing the stock to plunge. The company reported its Q3 2025 and Q4 2025 earnings, highlighting the FDA approval and U.S. launch of CARDAMYST. In mid-December 2025, Wells Fargo and HC Wainwright & Co. both doubled their price targets for MIST. In April 2026, Milestone Pharmaceuticals announced the RESET-PSVT Registry and reported that its EMA Marketing Authorization Application (MAA) for etripamil was accepted. In July and September 2024, Stuart Duty, Andrew Saik and Joseph Papa joined the board as independent directors.